141 related articles for article (PubMed ID: 16331604)
1. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
Ruiz C; Seibt S; Al Kuraya K; Siraj AK; Mirlacher M; Schraml P; Maurer R; Spichtin H; Torhorst J; Popovska S; Simon R; Sauter G
Int J Cancer; 2006 May; 118(9):2190-4. PubMed ID: 16331604
[TBL] [Abstract][Full Text] [Related]
2. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
3. 8p deletion is strongly linked to poor prognosis in breast cancer.
Lebok P; Mittenzwei A; Kluth M; Özden C; Taskin B; Hussein K; Möller K; Hartmann A; Lebeau A; Witzel I; Mahner S; Wölber L; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von der Assen A; Müller V; Burandt E
Cancer Biol Ther; 2015; 16(7):1080-7. PubMed ID: 25961141
[TBL] [Abstract][Full Text] [Related]
4. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade.
Nocito A; Bubendorf L; Tinner EM; Süess K; Wagner U; Forster T; Kononen J; Fijan A; Bruderer J; Schmid U; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Anabitarte M; Hering F; Hardmeier T; Schoenenberger AJ; Flury R; Jäger P; Fehr JL; Schraml P; Moch H; Mihatsch MJ; Gasser T; Sauter G
J Pathol; 2001 Jul; 194(3):349-57. PubMed ID: 11439368
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
6. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
8. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
9. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
11. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
12. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
[TBL] [Abstract][Full Text] [Related]
13. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
[TBL] [Abstract][Full Text] [Related]
14. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours.
Focke CM; Decker T; van Diest PJ
Histopathology; 2016 Nov; 69(5):849-861. PubMed ID: 27270560
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
18. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
